10.8 C
Friday, March 24, 2023

Propanc Biopharma Inc (OTCMKTS: PPCB) Storied OTC Biotech Moving Northbound After Significant Reversal (More on Successful Pre-Clinical Studies on PRP)

Propanc Biopharma Inc (OTCMKTS: PPCB) is a little-known biotech make some big moves on the bulletin board recently making a significant reversal off $0.0002 from where it has been moving up steadily on heavy accumulation with buys outnumbering sells 3 to 1 on Friday with PPCB closing up over 60% at $0.007. PPCB has a long and storied history on the bulletin boards and is an OG biotech in small caps. Over the years PPCB has made a number of historic runs first in 2015 and again in 2018 during which time PPCB was the most actively discussed stock on ihub, regularly traded $10 million plus in dollar volume and made parabolic moves northbound. 

PPCB recently made a significant reversal off $0.0002 after several years of decline and little interest from investors. As the stock hit its new 52 week lows the selling dried up and quickly buyers outnumbered sellers 3 to 1 and a consensus is building that something is brewing. The Company filed an 8k on February 15 that reported Propanc has retired its final convertible promissory note on 02/15/2023, the Company made full and final payment of the Note, leaving a zero balance remaining. Propanc has no remaining obligations to issue any of its securities to the Holder. We will be updating on PPCB when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Propanc Biopharma Inc (OTCMKTS: PPCB) is a biopharmaceutical company developing a novel approach to prevent recurrence and metastasis from solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer. Check out the Propanc investors presentation here.

Propanc’s lead product candidate, PRP, a variation upon the Comapny’s novel formulation and involves proenzymes, the inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of the technology, Propanc has conducted successful pre-clinical studies on PRP and also commenced preparation for a clinical study in advanced cancer patients. Subject to the Comapny receiving sufficient financing, it plans to begin its Investigational Medicinal Product Dossier, study proposal and Investigator’s Brochure in the 2023 calendar year. Propanc’s plan is to then commence its study preparation process with the contract research organization, analytical lab and trial site(s) selection and to begin our clinical trial application for PRP (“CTA”) compilation in the first calendar quarter of 2023 and complete the CTA compilation and submit the CTA in the first half of 2023. In the second quarter of 2023, Propanc plans to begin the preparation of logistics and trial site initiation visits. Subject to raising additional sufficient capital, we subsequently plan to commence a First-In-Human (FIH), Phase Ib study in patients with advanced solid tumors, evaluating the safety, pharmacokinetics and anti-tumor efficacy of PRP in the second half of 2023 calendar year, which study we hope to complete within twelve months thereafter. Propanc intends to develop its PRP to treat early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening. 

PRP is an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention. PRP is a combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen. PRP produces multiple effects on cancerous cells intended to inhibit tumor growth and potentially stop a tumor from spreading through the body. 

Propanc received notification from the U.S. Food and Drug Administration (FDA) that PRP had been conferred Orphan Drug Designation for the treatment of pancreatic cancer. This special status is granted when a rare disease or condition is implicated and a potential treatment qualifies under the Orphan Drug Act and applicable FDA regulations. 

A Certificate for Advance Overseas Finding was received from the Board of Innovation and Science Australia to receive up to a 43.5% “cash back” benefit from overseas R&D expenses. The finding relates to the planned Phase 1 clinical trial – Multiple Ascending Dose Studies of proteolytic proenzymes for the treatment of advanced cancer patients suffering from solid tumors planned to be conducted at the Peter MacCallum Center, Melbourne, Australia. Overseas activities to be undertaken include the development of an analytical assay for the quantification of active pharmaceutical ingredients in the Company’s lead product candidate, PRP, and its manufacture of the finished product for the Phase 1 clinical trial. 

To Find out the inside Scoop on PPCB Subscribe to Newsytrends.com Right Now by entering your Email in the box belowPPCB

Drug Discovery News on Twitter: "#Propanc #Biopharma develops #bioanalytical assay to detect active ingredients of anti-cancer PRP Test of trypsinogen/chymotrypsinogen combo critical to initial #clinicaltrials planned for early 2020 https://t.co ...Propanc’s POP1 joint research and drug discovery program is designed to produce a backup clinical compound to the lead product candidate, PRP. With the aim of producing large quantities of trypsinogen and chymotrypsinogen for commercial use, exhibiting minimal variation between lots and without sourcing the proenzymes from animals, Propanc Biopharma is undertaking a challenging research project in collaboration with the Universities of Jaén and Granada. We entered into a second two-year joint research and collaboration agreement with the University of Jaén who are undertaking the research activities for the POP1 program. 

In an 8k filed on February 22 Propanic reported it has retired its final convertible promissory note, dated June 30, 2022 in favor of 1800 Diagonal Lending LLC. The Note was previously disclosed in the Company’s Current Report on Form 8-K filed on July 7, 2022. On February 15, 2023, the Company initiated and made full and final payment of the Note, fully converting all outstanding principal and interest into shares of the Company’s common stock, leaving a zero balance remaining. Accordingly, the parties have no further rights or obligations as to each other as to the debt that had been memorialized by the Note, and the Company does not have any remaining obligations to issue any of its securities to the Holder. 

For More on PPCB Subscribe Right Now!

urrently trading at a $734,524 market valuation PPCB os is 1,836,310,391 with just 100 million shares in the float according to Otcmarkets.com. While the Company is pre revenue and doesn’t have the greatest balance sheet, they are an SEC filer and fully reporting and have $3 million in total liabilities which comparably speaking is pretty good on this exchange. Back in the day Propanc was one of the biggest movers in penny stocks regularly trading $10s of million in dollar volume and my articles on Propanc at the time at my prior newsletter regularly were seen by over 20,000 viewers and PPCB investors. At $0.0007 PPCB is one biotech reversal that deserves to be at the top of speculators’ watchlists.  We will be updating on PPCB when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PPCB either long or short and we have not been compensated for this article.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.